8 results about "Immunotoxin" patented technology

It is an object of the present invention to provide a compound that has absorption in a near infrared region, has high efficiency of singlet oxygen generation (quantum yield), and also has high tumor toxicity when it is combined with an immunotoxin. According to the present invention, provided is a compound represented by the following formula (1) or a salt thereof:wherein L1 and L2 each independently represent a single bond, —O—, —CO—, an alkylene group containing 1 to 8 carbon atoms, a sugar chain, or a combination thereof; R1 and R2 each independently represent an alkyl group containing 1 to 8 carbon atoms, a carboxylic acid group, an amino group, a hydroxyl group, a thiol group, or a biotin residue; R3, R4, R5, R6, R7 and R8 each independently represent an alkyl group containing 1 to 8 carbon atoms, a phenyl group, a carboxylic acid group, an amino group, a hydroxyl group, a thiol group, or a biotin residue; and M represents Mg, Zn, Fe, P, Si, Cu, Sn, Al, Ti, Mo, or Ni.

Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.

This invention relates to an immunotoxin targeting hematologic malignancies and its application. The immunotoxin comprises a toxic molecule and a carrier. The toxic molecule is pumpkin protein or a mutant of pumpkin protein. The carrier contains an antibody, ligand, or polypeptide capable of binding to hematologic malignancies cells. The antibody comprises an antibody fragment or a small molecule antibody. This invention provides an immunotoxin targeting hematologic malignancies for the treatment of these malignancies. The immunotoxin using a pumpkin protein mutant as the toxic molecule exhibits enhanced specificity against hematologic malignancies cells with high target expression, significantly increased activity in killing target cells, and allows for a substantial reduction in dosage and toxicity. In summary, the immunotoxin targeting hematologic malignancies using a pumpkin protein mutant as the toxic molecule offers advantages in both synergistic effect and reduced toxicity, and has broad application prospects.

Provided herein are engineered effector cells that include a toxin expressing module, wherein the toxin expressing module expresses a toxin, and wherein the engineered effector cell is resistant to the toxin. In some embodiments, the engineered effector cell further includes a chimeric antigen receptor (CAR), wherein the CAR binds specifically to a tumor antigen.

IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25.sup.+ and / or CCR4.sup.+ cutaneous T cell lymphoma, and other human CD25.sup.+ or CCR4.sup.+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25.sup.+ or CCR4.sup.+ Tregs.

Human anti-CD45 antibodies are described. The anti-CD45 antibodies can be engineered into numerous formats, such as antibody-radioisotope conjugates, antibody-immunotoxin conjugates, antibody-drug conjugates (ADCs), antibody-detectable label conjugates, antibody-nanoparticle conjugates, antibody-bead conjugates, multi-domain binding molecules, single chain variable fragments (scFv), and recombinant receptors and can be used as research, diagnostic, or therapeutic tools against CD45-related disorders. Examples of CD45 related disorders include cancers (solid tumors and hematologic malignancies such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)), infections, autoimmune disorders, and metabolic disorders, among other disorders described herein.

Methods of treating various types of cancer, including breast cancer, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C Motif Chemokine Receptor 4 immunotoxin alone or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an anti-programmed death-1 monoclonal antibody.

Methods of treating various types of cancer, including cutaneous T-cell lymphoma, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin, alone, or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an antibody-drug conjugate.